IBP0 Stock Overview
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Path Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.56 |
| 52 Week High | US$13.90 |
| 52 Week Low | US$6.56 |
| Beta | 0.38 |
| 1 Month Change | 0% |
| 3 Month Change | -15.90% |
| 1 Year Change | n/a |
| 3 Year Change | -91.59% |
| 5 Year Change | -97.93% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | n/a | -19.4% | -0.4% |
Return vs Industry: Insufficient data to determine how IBP0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how IBP0 performed against the German Market.
Price Volatility
| IBP0 volatility | |
|---|---|
| IBP0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IBP0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IBP0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 10 | Peter Nielsen | www.biopathholdings.com |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
Bio-Path Holdings, Inc. Fundamentals Summary
| IBP0 fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€15.11m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs IBP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBP0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.08m |
| Earnings | -US$16.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -21.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IBP0 perform over the long term?
See historical performance and comparison